A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

The development and growth of prostate cancer depends on the androgen receptor and its high-affinity binding of dihydrotestosterone, which derives from testosterone. Most prostate tumors regress after therapy to prevent testosterone production by the testes, but the tumors eventually recur and cause death. A critical question is whether the androgen receptor mediates recurrent tumor growth after androgen deprivation therapy. Here we report that a majority of recurrent prostate cancers express high levels of the androgen receptor and two nuclear receptor coactivators, transcriptional intermediary factor 2 and steroid receptor coactivator 1. Overexpression of these coactivators increases androgen receptor transactivation at physiological concentrations of adrenal androgen. Furthermore, we provide a molecular basis for this activation and suggest a general mechanism for recurrent prostate cancer growth.

[1]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[2]  N. Weigel,et al.  8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein , 2000, Molecular and Cellular Biology.

[3]  J. A. Kemppainen,et al.  FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor* , 2000, The Journal of Biological Chemistry.

[4]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[5]  H. Gronemeyer,et al.  Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.

[6]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[7]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[8]  G. Coetzee,et al.  Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins , 1999, Molecular and Cellular Biology.

[9]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[10]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[11]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[12]  J. A. Kemppainen,et al.  Intermolecular NH2-/Carboxyl-terminal Interactions in Androgen Receptor Dimerization Revealed by Mutations That Cause Androgen Insensitivity* , 1998, The Journal of Biological Chemistry.

[13]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[14]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[15]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[16]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[17]  E. Langley,et al.  Evidence for an Anti-parallel Orientation of the Ligand-activated Human Androgen Receptor Dimer (*) , 1995, The Journal of Biological Chemistry.

[18]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[19]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[20]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[21]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. H. van der Kwast,et al.  Androgen receptor expression in human tissues: an immunohistochemical study. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  F. S. French,et al.  Androgen Regulation of HBGF-I (aFGF) mRNA and Characferization of the Androgen-Receptor mRNA in the Human Prostate Carcinoma Cell Line-LNCaP/A-Dep , 1991 .

[24]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[25]  F. S. French,et al.  Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity , 1989, Proceedings of the National Academy of Sciences of the United States of America.